A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

NCT00169156 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Untreated T-cell Angioimmunoblastic Lymphoma

Interventions

DRUG: Rituximab
DRUG: Prednisone
DRUG: Doxorubicine
DRUG: Cyclophosphamide
DRUG: Vincristine

Sponsor

Lymphoma Study Association

Collaborators

[object Object]